Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi 4Q Results | Contract Pharma

What are you searching for?

Sign in
Financial News

Sanofi 4Q Results

Revenues up 7% in the quarter despite €801 million loss.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Sanofi

Sanofi

4Q Revenues: €11.3 billion +7%

4Q Loss: €801 million -261%

FY Revenues: €43.6 billion +6%

FY Earnings:  €7.8 billion +41%

Comments: Dupixent sales were €4.2 billion in the quarter, up 32%. Lantus sales were €419 million, up 1%. Toujeo sales were €332 million, up 19%. Fabrazyme sales were €252 million, down 1%. Plavix sales were up 7.6% to €214 million in the quarter. Lovenox sales were $179 million, down 21.6% impacted by increasing competition. Cerezyme sales were €171 million up 3%. The Gaucher disease franchise (Cerezyme and Cerdelga) sales were €254 million and increased by 1.6%. Alprolix sales were €149 million, down 4%.

Vaccine sales were down 2.5% in the quarter to €2.0 billion. Beyfortus sales were down 15% to €686 million. Influenza, COVID-19 vaccines sales were up 31.5 % to €575 million in the quarter. Polio/Pertussis/Hib (PPH) primary and booster vaccines sales were €551 million down 9.5%. Meningitis, travel, and endemic vaccines sales were €227 million, down 5%.

*Changes in net sales are at constant exchange rates (CER).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics